Imatinib Mesylate Tablet, Film Coated
Product Images NDC 0904-6901

8 FDA label images from Major Pharmaceuticals · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Imatinib Mesylate (NDC 0904-6901). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Imatinib-molecule (Imatinib Molecule)

Imatinib-molecule (Imatinib Molecule)
Chemical structure of Imatinib Mesylate, showing its molecular framework including aromatic rings, amine groups, and the mesylate moiety (methanesulfonic acid group).*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A Kaplan-Meier curve showing the percentage of patients without progression over time in months since randomization. The graph compares two treatment arms: Imatinib Mesylate Arm (solid line) and IFN+Ara-C Arm (dashed line). The chart includes patient numbers with progression, censored at discontinuation and last follow-up, as well as a hazard ratio with 95% confidence interval and log-rank test p-value.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A line graph comparing the percentage of patients without progression to AP or BC over 72 months since randomization for two groups: Imatinib Mesylate Arm (solid line) and IFN+ARA-C Arm (dashed line). The graph includes patient numbers and a hazard ratio with confidence interval and p-value.*
FDA Label Image

Fig 3.jpg (Fig 3)

Fig 3.jpg (Fig 3)
A survival curve graph showing the probability of being alive and recurrence-free over time in months for patients treated with Imatinib 400 mg compared to placebo. The graph includes two lines representing each group, with symbols indicating censored data points and a table below listing patients at risk at various time intervals up to 96 months.*
FDA Label Image

Fig 4.jpg (Fig 4)

Fig 4.jpg (Fig 4)
A Kaplan-Meier survival curve chart showing the probability of recurrence-free survival over time in months for two Imatinib treatment groups: 12 months and 36 months. The chart includes censored observations and a table of at-risk events below with statistical data such as a p-value, hazard ratio, and confidence interval.*
FDA Label Image

Fig 5.jpg (Fig 5)

Fig 5.jpg (Fig 5)
A survival curve chart depicting the probability of overall survival over time in months for two groups treated with Imatinib Mesylate at 12 months and 36 months. The chart includes hazard ratio and confidence interval values, censored observations marked, and a table showing the number of subjects at risk and events at different time points.*
FDA Label Image

100mg Carton Label (16f7a4e3 18ba 2873 9fe1 852d7befcab4 01)

100mg Carton Label (16f7a4e3 18ba 2873 9fe1 852d7befcab4 01)
Imatinib Mesylate 100 mg film-coated tablets label from Major Pharmaceuticals. The unit dose package contains 30 tablets (3 blister packs of 10 tablets each). The label includes NDC 0904-6901-04, storage and dispensing instructions, and a barcode. Product is for prescription use only.*
FDA Label Image

400mg Carton Label (16f7a4e3 18ba 2873 9fe1 852d7befcab4 00)

400mg Carton Label (16f7a4e3 18ba 2873 9fe1 852d7befcab4 00)
Imatinib Mesylate 400 mg film-coated oral tablets by Major Pharmaceuticals. The label shows a unit dose package containing 30 tablets (3 x 10) with NDC 0904-6621-04. Includes storage instructions, dosage note, and a statement that the package is for institutional use only and not child resistant. Barcode and distributor information are also visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.